FDA Expands Approval of ImmunityBio's Anktiva to Include Early-Stage Bladder Cancer
The U.S. Food and Drug Administration (FDA) has expanded the approval of ImmunityBio’s drug, Anktiva (nogapendekin albakicept), for treating non-muscle invasive bladder cancer in patients who are unresponsive to Bacillus Calmette-Guérin (BCG). This marks a significant milestone as it broadens access to this treatment option. The decision was based on clinical evidence supporting the drug’s efficacy and safety profile, allowing earlier use of Anktiva for adult patients with high-risk bladder cancer. This expanded approval could position ImmunityBio more favorably in the oncology market by addressing a critical unmet need among BCG-unresponsive patients. It may also lead to increased sales potential as healthcare providers adopt this new indication into treatment protocols, potentially boosting investor confidence and stock performance for IBRX.
Tickers: $IBRX
Topics: cancer_treatment pharmaceuticals
Read the full article at Seeking Alpha
Part of the story FDA Expands Approval of ImmunityBio's Anktiva to Include Early-Stage Bladder Cancer (2 articles)